Challenge Transfusion of INTERCEPT Pathogen Reduced Red Blood Cells (RBCs) in Subjects With or Without Pre-existing Antibodies to INTERCEPT RBCs

Launched by CERUS CORPORATION ·

Keywords

ClinConnect Summary

This clinical trial is studying a special type of blood transfusion using red blood cells (RBCs) treated with a technology called INTERCEPT, which helps reduce the risk of infections. The main goal is to see how safe and effective these treated blood cells are in people who may already have antibodies (proteins made by the immune system) against INTERCEPT RBCs, as well as those who do not. Researchers want to find out if receiving these treated cells causes an immune reaction, leads to the blood cells being removed from the body too quickly, or causes any side effects like hemolysis, which is when red blood cells break down.

The study is open to adults of all genders and will include two groups: one with people who have these pre-existing antibodies and one without, to compare results. If you join this trial, you can expect to receive INTERCEPT-treated red blood cells and undergo tests to monitor your immune response and how well the transfused cells survive in your body. The study will also explore new ways to test compatibility between blood donors and recipients using special lab tests. This trial is not yet recruiting but aims to help improve the safety of blood transfusions in the future.

Gender

ALL

Eligibility criteria